Cardiovascular Health 2025

Neo · 2025-10-16T03:56:15.758Z

RapAdmin:

SGLT2 inhibitors

@adssx do you how big the HDL effect is from flozinz? Do you think it’s helpful HDL up or just spurious (like the first gen CETP drugs seem to have perhaps been)

adssx · 2025-10-19T13:50:29.301Z

The effect of SGLT2i on HDL does not seem to be clinically significant: https://www.atherosclerosis-journal.com/article/S0021-9150(23)05153-5/fulltext

CronosTempi · 2025-10-24T00:27:44.652Z

New treatment cuts cholesterol by nearly 50%, without statins or side effects

ScienceDaily

New treatment cuts cholesterol by nearly 50%, without statins or side effects

Researchers have developed a DNA-based therapy that targets the PCSK9 gene to lower cholesterol naturally. Using polypurine hairpins, they increased cholesterol uptake by cells and reduced artery-clogging lipid levels. The results show dramatic drops...

Inhibition of PCSK9 with polypurine reverse hoogsteen hairpins: A novel gene therapy approach

https://www.sciencedirect.com/science/article/pii/S0006295225002382?via%3Dihub

Davin8r · 2025-10-24T01:04:55.725Z

Just wanted to report that my insurance covers Nexlizet with NO prior authorization for $10/month ($25 for 90 days). I could have saved so much money by asking my doc years ago to “just prescribe it and see what happens”.

I figured for sure they wouldn’t do it since my LDL is already low and I’m on Repatha. Lesson is, don’t assume your insurance won’t cover it if you want to try bempedoic acid. And now I’ll be using the branded med rather than a foreign generic with the associated potential risks.

DeStrider · 2025-10-24T02:04:56.680Z

Heart Disease Drug VTX3232 Reduces Inflammation (HS-CRP) by 64%

New Heart Disease Drug in Phase 2 testing. Citing initial results from a Phase 2 trial for the once-daily drug in patients with cardiovascular risk factors and obesity, the California-based biopharma said VTX3232 was safe and well-tolerated among study subjects. The 12-week study evaluated VTX3232’s safety and tolerability as its primary goal, and the company measured the drug’s effect on high-sensitivity C-reactive protein (hsCRP) as the trial’s secondary goal related to inflammation. As for hsCRP levels in the full analysis, there was a 64% reduction in the biomarker from baseline among patients treated with VTX3232 compared to a 3% rise in the placebo group. “These results support further development and VTX3232’s potential to address the high burden of disease caused by inflammation,” said Ventyx’s (NASDAQ:VTYX) medical chief, Mark Forman. http://seekingalpha.com/news/4507405-ventyx-up-mid-stage-trial-data-heart-drug

Russel_Morris · 2025-10-24T21:41:51.617Z

Consensus is that statins have a material effect on lifespan and healthspan.

Curious thoughts about this study that seems tl suggest they do for people who already have CAD but dont have a significant effect for those who dont.

So tear it apart

https://www.jacc.org/doi/abs/10.1016/j.jcmg.2025.05.018?utm_source=signals.superpower.com&utm_medium=newsletter&utm_campaign=cholesterol-genes-drugs-cancer-clues-and-women-bodybuilders&_bhlid=25104835387f7d8d78d10130c3479b0ca0173506

Virilius · 2025-10-24T22:14:16.436Z

Which age group makes up the overwhelming majority of deaths from ASCVD? Old people.
Which age group already mostly has CAD? Old people.
Old people who don’t have any calcified plaque in their blood vessels already either have low LDL-C or are genetically protected from the negative effect of cholesterol through various mechanisms in which case statins don’t have much of an effect.

RapAdmin · 2025-10-25T06:36:24.103Z

Association of dietary omega-3 fatty acids intake with all-cause and cardiovascular disease-specific mortality among individuals with cardiovascular disease

In the separate analysis of individual subtypes of the omega-3 fatty acid family, the consumption of alpha-linolenic acid (ALA) was obviously inverse-associated with CVD-specific mortality (HR of 0.64, 95% CI: 0.44–0.95). Nonetheless, the consumption of eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA) did not show a significant association with mortality risk (P > 0.05).

In the dose-response relationship analysis, total omega-3 fatty acid intake and ALA intake were observed to have an “L”-shaped nonlinear relationship with cardiovascular mortality, with the inflection points at 2.12 (g/day) and 2.03 (g/day), respectively. In summary, our research indicates that both total omega-3 fatty acids and ALA are inversely linked to the risk of all-cause mortality and cardiovascular mortality in patients with CVD.

We recommend a daily intake of 2.12 g of total omega-3 fatty acids, with an optimal intake of 2.03 g/day for ALA for CVD patients.